What is HC Wainwright’s Estimate for IKT Q1 Earnings?

Inhibikase Therapeutics, Inc. (NYSE:IKT) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Inhibikase Therapeutics in a research report issued to clients and investors on Wednesday, February 12th. HC Wainwright analyst E. White expects that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.56) EPS.

Separately, Jefferies Financial Group started coverage on shares of Inhibikase Therapeutics in a research note on Friday, November 8th. They issued a “buy” rating and a $8.00 price target for the company.

Inhibikase Therapeutics Trading Up 5.4 %

Shares of Inhibikase Therapeutics stock opened at $2.35 on Monday. The business has a fifty day simple moving average of $2.88 and a two-hundred day simple moving average of $2.18. The firm has a market capitalization of $163.00 million, a P/E ratio of -0.88 and a beta of 1.06. Inhibikase Therapeutics has a 12 month low of $1.12 and a 12 month high of $4.20.

Institutional Trading of Inhibikase Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp bought a new stake in Inhibikase Therapeutics in the fourth quarter worth $43,000. Alpine Global Management LLC purchased a new position in Inhibikase Therapeutics in the 4th quarter worth about $48,000. Northern Trust Corp purchased a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at approximately $208,000. Barclays PLC bought a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at $273,000. Finally, Blair William & Co. IL boosted its stake in shares of Inhibikase Therapeutics by 7.0% in the 4th quarter. Blair William & Co. IL now owns 134,953 shares of the company’s stock worth $439,000 after buying an additional 8,833 shares during the last quarter. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.